Research on effects of bone marrow mononuclear cells implantation on model of experimental pulmonary artery hypertension.
- Author:
Yan LU
1
;
Zhaohua ZHANG
;
Guanghui CHENG
;
Yun LUAN
Author Information
1. Department of Pathology, Hospital of Beihang University, Beijing 100191, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Bone Marrow Cells;
cytology;
Cell Transplantation;
methods;
Dogs;
Familial Primary Pulmonary Hypertension;
Female;
Hypertension, Pulmonary;
chemically induced;
therapy;
Leukocytes, Mononuclear;
transplantation;
Male;
Monocrotaline;
analogs & derivatives;
Rats
- From:
Journal of Biomedical Engineering
2013;30(3):601-606
- CountryChina
- Language:Chinese
-
Abstract:
In the present study, we carried out intratracheal administration of bone marrow-derived mononuclear cells (BM-MNCs) to dehydromonocrotaline (DMCT)-induced canine pulmonary artery hypertension (PH) of rat model to examine the security and feasibility, and the aim was to discuss the mechanism. All animals (n=30) were randomly divided into 3 groups (n=10 in each group), i. e. control group, PH group and BM-MNCs group. Six weeks after the transplantation, the hemodynamic data and right ventricle weight ratio were significantly improved for those in BM-MNCs group compared with those in PH group. The lung mRNA levels of vascular endothelial growth factor (VEGF) were higher, while preproendothelin-1 (ppET-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) were lower compared with those in the PH group (P<0. 05). Immunofluorescence and histochemical results confirmed that 6 weeks after the administration, transplanted BM-MNCs were still alive and could differentiate into pulmonary vascular endothelial cells. These results showed that intratracheal administration of BM-MNCs could obviously reduce or even reverse the DMCT induction of PAH process. The mechanism could be explained as that the function was mainly through the paracrine effect to promote renewable and reduce inflammation.
